Clarivate: Drugs to Watch 2026

For Drugs to Watch 2026, our team of analysts systematically selected eleven therapeutics that are likely to transform treatment paradigms and/or become blockbusters in the next five years. We provide an overview of our methodology and summaries of the selected drugs on this site. Our in-depth analysis and drug descriptions are available in the downloadable full report.


This year’s Drugs to Watch include next-generation GLP-1 drugs for weight loss and type 2 diabetes mellitus (T2DM), targeted protein degraders for cancer, precision medicines for rare diseases and new therapies in women’s health.
Download the Drugs to Wat
ch 2026 reportdownload


2026 Drugs to Watch

Explore detailed summaries and analyst commentary on each drug





Drugs to Watch2026

BGB-16673


Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
north_east
Drugs to Watch2026

Exdensur (depemokimab)


Asthma
north_east
Drugs to Watch2026

Gedatolisib


Breast cancer
north_east
Drugs to Watch2026

Icotrokinra


Plaque psoriasis
north_east
Drugs to Watch2026

INLEXZO™ (TAR-200)


Bladder cancer
north_east
Drugs to Watch2026

Mezigdomide


Multiple myeloma
north_east
Drugs to Watch2026

Orforglipron


Obesity, Type 2 diabetes mellitus (T2DM)
north_east
Drugs to Watch2026

Relacorilant


Ovarian cancer and hypercortisolism (Cushing syndrome)
north_east
Drugs to Watch2026

Retatrutide


Obesity, Type 2 diabetes mellitus (T2DM)
north_east
Drugs to Watch2026

Tolebrutinib


Multiple sclerosis
north_east
Drugs to Watch2026

VOYXACT® (sibeprenlimab)


IgA nephropathy
north_east


How we identified the Drugs to Watch

Since 2013, our annual Drugs to Watch report has relied on our proprietary technologies, tools and techniques that are also trusted by our global life sciences customers.

To identify the Drugs to Watch 2026 list, we drew from expertise from over 160 Clarivate analysts covering hundreds of diseases, drugs and markets and 10 integrated, AI-enhanced data sets that span the R&D and commercialization lifecycle. For the first time this year, we validated our findings using AI platforms and grouped the drugs by industry-relevant trends.
Learn more about our methodology
north_east

Industry trends driving innovation

Patients’ needs and expectations are reshaping biopharma as regulators push for innovation that results in meaningful outcomes. Together, they are driving progress across global health priorities including the obesity crisis, rare-yet-extremely burdensome conditions, women’s health and hard-to-treat cancers, showing how science and policy can align to advance care and close treatment gaps.

Our Drugs to Watch for 2026 reflect this dynamic, aligning roughly to these four key trends:
The race to revinvent weight lossnorth_east
Bridging the rare disease treatment gapnorth_east
Rethinking the research paradigm for women’s healthnorth_east
Redefining targetability with protein degradersnorth_east

https://clarivate.com/drugs-to-watch/